Company Profile

  1. You are here:    Home
  2. Search Databases
  3. Search Company Registry
  4. Company Profile

Illexcor Therapeutics LLC
Profile last edited on: 2/15/2021      CAGE: 88YN7      UEI: GFKZPH9N1VX3

Business Identifier: Innovative therapies for blood disorder
Year Founded
2018
First Award
2020
Latest Award
2024
Program Status
Active
Popularity Index

Edit Company Profile

Is this YOUR Company?
Ensure accuracy and completeness of YOUR Company Profile by completing the brief Survey Instrument attached
Do you know about this Awardees?
Let us encourage you to provide any data which would enhance the completeness of this firm's profile.
  Explanation Edit

Location Information

800 East Leigh Street Suite 19
Richmond, VA 23219
   (804) 305-2594
   N/A
   www.illexcor.com
Location: Single
Congr. District: 04
County: Richmond city

Public Profile

Illexcor Therapeutics is structured around discovery and development of new therapeutics to treat a range of blood-related diseases and conditions, including Sickle Cell Disease, hypoxia, and ischemia.

Extent of SBIR involvement

User Avatar
Phase I Awards
3
Phase II Awards
2
Conversion Rate
66.67%
Phase I Dollars
$898,374
Phase II Dollars
$3,418,063
Total Awarded
$4,316,437

Synopsis: Awardee Business Condition

Employee Range
1-4
Revenue Range
Less than .5M
VC funded?
No
Public/Private
Privately Held
Stock Info
----
IP Holdings
N/A

Awards Distribution by Agency

Most Recent SBIR Projects
Year Phase Agency Total Amount
2023 2 NIH $1,851,828
Project Title: Novel therapeutic approach for severe ARDS with a potent pharmacologic allosteric hemoglobin modifier
2023 2 NIH $2,164,647
Project Title: Rapid Development of a Lead Aromatic Aldehyde Derivative with Both Oxygen Dependent and Novel, Oxygen Independent Anti-Sickling Effects: Building on a Paradigm Shift in Sickle Cell Disease Therapy
2020 1 NIH $299,962
Project Title: Prodrugs and Derivatives of Hydroxymethylfurfural (5-Hmf) to Develop a Novel, Bioavailable Treatment for Sickle Cell Disease

Key People / Management

  James Burnett

  David Light

Company News

There are no news available.